These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1849164)

  • 21. [Efficacy and tolerance of a combination of AZT, DDC, and saquinavir in patients infected with the human immunodeficiency virus].
    Soriano Vázquez V; Rodríguez-Rosado Martínez-Echevarría R; Jiménez-Nacher I; Valencia Ortega E; Moreno Celda V; González-Lahoz J
    Rev Clin Esp; 1998 Sep; 198(9):634-5. PubMed ID: 9803794
    [No Abstract]   [Full Text] [Related]  

  • 22. Intermittent selection pressure with zidovudine plus zalcitabine treatment reduces the emergence in vivo of zidovudine resistance HIV mutations.
    Izopet J; Sailler L; Sandres K; Pasquier C; Bonnet E; Aquilina C; Puel J; Massip P; Marchou B
    J Med Virol; 1999 Feb; 57(2):163-8. PubMed ID: 9892402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of murine retrovirus-induced immunodeficiency disease by dideoxycytidine and dideoxycytidine 5'-triphosphate.
    Rossi L; Brandi G; Fraternale A; Schiavano GF; Chiarantini L; Magnani M
    J Acquir Immune Defic Syndr (1988); 1993 Nov; 6(11):1179-86. PubMed ID: 8229653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 3TC/AZT: just another combination.
    GMHC Treat Issues; 1995 Dec; 9(12):2. PubMed ID: 11362997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).
    Yarchoan R; Perno CF; Thomas RV; Klecker RW; Allain JP; Wills RJ; McAtee N; Fischl MA; Dubinsky R; McNeely MC
    Lancet; 1988 Jan; 1(8577):76-81. PubMed ID: 2891981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ACTG 175 and Delta.
    Torres G
    GMHC Treat Issues; 1995 Oct; 9(10):2-3. PubMed ID: 11362915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of murine AIDS by combination of AZT and dideoxycytidine 5'-triphosphate.
    Fraternale A; Casabianca A; Rossi L; Chiarantini L; Brandi G; Aluigi G; Schiavano GF; Magnani M
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jun; 12(2):164-73. PubMed ID: 8680888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ACTG 175: new insights into treating patients with intermediate-stage HIV disease.
    Folkers G
    NIAID AIDS Agenda; 1995 Dec; ():4-5. PubMed ID: 11363352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of AIDS with combinations of antiretroviral agents.
    Merigan TC
    Am J Med; 1991 Apr; 90(4A):8S-17S. PubMed ID: 1850192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Study results at a glance.
    AIDS Alert; 1995 Nov; 10(11):134. PubMed ID: 11362922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue.
    Mathé G; Pontiggia P; Orbach-Arbouys S; Triana K; Ambetima N; Morette C; Hallard M; Blanquet D
    Biomed Pharmacother; 1996; 50(5):220-7. PubMed ID: 8949403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Theoretical mechanistic basis of the toxic effects and efficacy of AZT in HIV: AIDS.
    Akintonwa DA
    Med Hypotheses; 2002 Dec; 59(6):622-5. PubMed ID: 12445499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 3TC: the good news and the bad news.
    Cheng B
    PI Perspect; 1995 May; (no 16):4. PubMed ID: 11362426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro synergistic inhibition of human bone marrow hemopoietic progenitor growth by a 3'-azido-3'-deoxy-thymidine, 2',3'-dideoxycytidine combination.
    Lerza R; Castello G; Mela GS; Arboscello E; Cerruti A; Bogliolo G; Mencoboni M; Ballarino P; Pannacciulli I
    Exp Hematol; 1997 Mar; 25(3):252-5. PubMed ID: 9091302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AZT/ddC combination may benefit AIDS sufferers.
    Oncology (Williston Park); 1989 Jan; 3(1):107. PubMed ID: 2561878
    [No Abstract]   [Full Text] [Related]  

  • 37. Benefits of combination therapy confirmed.
    Cheng B
    PI Perspect; 1995 Dec; (no 17):3-4. PubMed ID: 11363111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 3TC and AZT.
    Treat Rev; 1995; (no 17):2. PubMed ID: 11362294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dideoxycytidine (ddC): a potent antiretroviral agent for human immunodeficiency virus infection. An introduction.
    Broder S
    Am J Med; 1990 May; 88(5B):1S. PubMed ID: 2159701
    [No Abstract]   [Full Text] [Related]  

  • 40. Inhibition of murine AIDS by alternate administration of azidothymidine and fludarabine monophosphate.
    Fraternale A; Casabianca A; Tonelli A; Vallanti G; Chiarantini L; Brandi G; Celeste AG; Magnani M
    J Acquir Immune Defic Syndr; 2000 Mar; 23(3):209-20. PubMed ID: 10839656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.